BERMUDA-BUSINESS-DEVELOP
11.5.2023 20:34:29 CEST | Business Wire | Press release
Bermuda’s Deputy Premier, The Hon. Walter Roban, JP, MP will kick off the second annual Bermuda Climate Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with KBRA on June 26.
The Deputy Premier will discuss Bermuda’s key attributes as the world’s climate risk finance capital in a keynote seaside chat with Mark Baker, President & CEO, KBRA.
Deputy Premier Roban said, “I look forward to once again participating in the Bermuda Climate Summit in order to highlight Bermuda’s strengths in climate risk finance, including our strong regulatory environment, long-history of environmental stewardship and wealth of financial services experience.”
The keynote address will be given by Joshua Rosenberg, Chief Risk Officer, Federal Reserve Bank of New York.
Other sessions confirmed to date include: The Power of Partnerships, which will be moderated by Jeff Manson, SVP Underwriting and Head of Global Public Sector Partnership, Renaissance Re Ltd, and will include panellists, Ekhosuehi Iyahen, Secretary General, Insurance Development Forum, Sid Miller, Director, Climate Wise, Rebekah Clement, Head of Sustainability, Lloyds, and Chair of SMI Climate Action Committee, and Tim Nielander, Founder and President, GP3 Institute.
Impact of a Changing Climate on Atlantic Hurricane Frequency and Severity will be moderated by Marla Pourrabbani, Data Scientist, Senior Manager, ESG and Sustainability, Deloitte, and features panellists, Dr. Pete Dailey, Head of Research, Aeolus, Liz Henderson, Co-Head Catastrophe Analytics, Executive Managing Director, Reinsurance Solutions, Aon, Dr. Peter Sousounis, Vice President/Director Climate Change Research, Verisk, Craig Tillman, President, RenaissanceRe Risk Sciences.
Net Zero? will be moderated by Miqdaad Versi, Head of ESG, Oxbow Partners, UK, and feature panellists Rachael Dalheise. Head of Sustainability, Convex, Andrew MacFarlane, Head of Climate, AXA XL, a Division of AXA, and Andrew Smith, Chief Risk and Sustainability Officer at Conduit Re.
Global Climate Risk will include Dr. Mark Guishard, former Director, Bermuda Weather Service, Dr. Raveem Ismail, Head of Parametric Underwriting, Africa Specialty Risks (ASR Re) and Dr. Simon Young, Senior Director, Willis Towers Watson.
What’s Ahead in the United States? will be moderated by John Huff, President & CEO, Association of Bermuda Insurers and Reinsurers (ABIR) and include panellists, Ricardo Lara, Insurance Commissioner, California Department of Insurance and Lori Wing-Heier, Director, Alaska Division of Insurance, and National Association of Insurance Commissioners (NAIC) Representative, Sustainable Insurance Forum.
Chlora Lindley-Myers, NAIC President and Director of the Missouri Department of Commerce and Insurance will speak on a panel entitled The U.S. Federal Flood Programme and the (Re)Insurance Sector, moderated by Peter Giacone, Global Head of Insurance, KBRA and including fellow panellists, Chris Brown – Partner, Mindset and Andy Neal, Managing Director, Public Private Partnerships, Aon.
David Hart, BDA, CEO said, “The theme of this year’s event is ‘Bermuda - Climate Central’ and we are honoured to have Deputy Premier Roban join us to open the 2023 Bermuda Climate Summit. We are equally pleased to have so many leading climate experts across different fields coming to Bermuda to engage with our audience on why climate is such an important topic. We also look forward to meeting with potential overseas investors to share why Bermuda is the perfect place to develop climate risk finance solutions.”
Click here to register for this important event. Overseas guests are also reminded to book their hotel rooms online before May 25, to enjoy special rates at our event hotel, the Hamilton Princess & Beach Club.
The BDA is grateful for the continued support of our headline sponsor KBRA, as well as: diamond sponsor Conduit Re; platinum sponsor Aon, gold sponsors Deloitte, Fidelis and Hub Culture; and silver sponsors Aeolus, Aspen, AXA XL, Belco, and KPMG. Our supporting sponsors are Butterfield and HSBC. Our media partners are The Insurer, Insurance Insider and Bermuda:Re+ILS. Goslings is our spirits partner. Other sponsorship opportunities are still available; please e-mail bermudaclimate@bda.bm if you wish to participate.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
